LEUVEN, Belgium, April 28 /PRNewswire/ -- Terumo Europe N.V., an affiliate of Terumo Corporation, Japan, a global medical technology company, announced today the opening of a branch office in Switzerland. Located in Wettingen, the new office's focus will be the promotion of the company's large range of innovative technologies including vascular interventional systems, blood transfusion systems and perfusion systems for cardiac surgery.
(Logo: http://www.newscom.com/cgi-bin/prnh/20061027/DEF004LOGO )
The Swiss location will play a vital role in the launch of such key new products as Nobori(R), a new generation of drug-eluting stent used in patients suffering from coronary artery disease, and Misago(TM), a peripheral self-expanding stent indicated for femoral and popliteal artery disease. Terumo anticipates benefits from close collaboration with key doctors and research institutions in Switzerland in the areas of product development and clinical trials.
"Switzerland is home to many of the world's largest healthcare companies and the opening of a Terumo presence in this market presents a tremendous growth opportunity for our company," said Hideo Arase, President and CEO of Terumo Europe N.V.
Terumo has been active in the Swiss market for more than 30 years working together with local distribution partners. Cosanum AG, a longtime Terumo partner, will continue to distribute Terumo hospital products such as the well-known Terumo(R) brand needles and syringes in Switzerland.
The Swiss branch office, located at Bahnhofstrasse 88 in Wettingen, is a subsidiary of Terumo Deutschland GmbH based in Eschborn, Germany.
Terumo Corporation, Tokyo, Japan is a global manufacturer of medical devices with 2007 annual revenues in excess of $2.5 billion. Terumo Corporation develops, manufactures, and markets a wide range of medical products including cardiovascular and vascular intervention systems, disposable medical devices, therapeutic catheters, I.V. solutions, blood bags, diabetes care systems, and medical electronic products in more than 150 countries worldwide.
SOURCE Terumo Europe N.V.